Context. Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, exhibits a
drug interaction with proton pump inhibitors (PPIs) and histamine-2 receptor antagonists …

Purpose Acid-suppression therapy is known to decrease the systemic exposure of erlotinib.
The erlotinib prescribing information recommends staggering dosing with a histamine-2 …

The aim of this study was to evaluate the effect of coadministration of acid-reducing agents
on the pharmacokinetic exposure of orally administered epidermal growth factor receptor …

Background: Erlotinib is used for treating non–small cell lung cancer (NSCLC). Intestinal
absorption of erlotinib is impaired under gastric pH elevation; therefore, coadministration of …

Abstract On November 18, 2004, erlotinib (Tarceva®; OSI Pharmaceuticals, Inc., Melville,
NY, http://www. osip. com, and Genentech, Inc., South San Francisco, CA, http://www. gene …

Objectives As the bioavailability of erlotinib is dependent on gastric pH, an increase in
gastric pH via the concurrent use of gastric acid suppressive medications (AS) may reduce …

AIMS There is increasing evidence that erlotinib exposure correlates well with treatment
outcome. In this report we present a case of therapeutic drug monitoring of erlotinib in a …

Erlotinib and Gastric Acid–Reducing Agents: A Combination to Avoid or to Support? Page 1
nature publishing group PERSPECTIVES To the Editor: We read with great interest Zhang …

Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …

Purpose Erlotinib depends on stomach pH for its bioavailability. When erlotinib is taken
concurrently with a proton pump inhibitor (PPI), stomach pH increases, which results in a …